Cargando…

Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies

The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. Many experimental HIV-1 vaccine efforts are therefore aimed at eliciting broadly neutralizing antibodies (bNAbs) that are capable of neutra...

Descripción completa

Detalles Bibliográficos
Autores principales: Brinkkemper, Mitch, Sliepen, Kwinten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789800/
https://www.ncbi.nlm.nih.gov/pubmed/31362378
http://dx.doi.org/10.3390/vaccines7030076
_version_ 1783458696972468224
author Brinkkemper, Mitch
Sliepen, Kwinten
author_facet Brinkkemper, Mitch
Sliepen, Kwinten
author_sort Brinkkemper, Mitch
collection PubMed
description The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. Many experimental HIV-1 vaccine efforts are therefore aimed at eliciting broadly neutralizing antibodies (bNAbs) that are capable of neutralizing the majority of circulating HIV-1 strains. The envelope glycoprotein (Env) trimer on the viral membrane is the sole target of bNAbs and the key component of vaccination approaches aimed at eliciting bNAbs. Multimeric presentation of Env on nanoparticles often plays a critical role in these strategies. Here, we will discuss the different aspects of nanoparticles in Env vaccination, including recent insights in immunological processes underlying their perceived advantages, the different nanoparticle platforms and the various immunogenicity studies that employed nanoparticles to improve (neutralizing) antibody responses against Env.
format Online
Article
Text
id pubmed-6789800
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67898002019-10-16 Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies Brinkkemper, Mitch Sliepen, Kwinten Vaccines (Basel) Review The enormous sequence diversity between human immunodeficiency virus type 1 (HIV-1) strains poses a major roadblock for generating a broadly protective vaccine. Many experimental HIV-1 vaccine efforts are therefore aimed at eliciting broadly neutralizing antibodies (bNAbs) that are capable of neutralizing the majority of circulating HIV-1 strains. The envelope glycoprotein (Env) trimer on the viral membrane is the sole target of bNAbs and the key component of vaccination approaches aimed at eliciting bNAbs. Multimeric presentation of Env on nanoparticles often plays a critical role in these strategies. Here, we will discuss the different aspects of nanoparticles in Env vaccination, including recent insights in immunological processes underlying their perceived advantages, the different nanoparticle platforms and the various immunogenicity studies that employed nanoparticles to improve (neutralizing) antibody responses against Env. MDPI 2019-07-29 /pmc/articles/PMC6789800/ /pubmed/31362378 http://dx.doi.org/10.3390/vaccines7030076 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Brinkkemper, Mitch
Sliepen, Kwinten
Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies
title Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies
title_full Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies
title_fullStr Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies
title_full_unstemmed Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies
title_short Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies
title_sort nanoparticle vaccines for inducing hiv-1 neutralizing antibodies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789800/
https://www.ncbi.nlm.nih.gov/pubmed/31362378
http://dx.doi.org/10.3390/vaccines7030076
work_keys_str_mv AT brinkkempermitch nanoparticlevaccinesforinducinghiv1neutralizingantibodies
AT sliepenkwinten nanoparticlevaccinesforinducinghiv1neutralizingantibodies